Originally published in 1977, Open Prisons presents research carried out in a number of prisons in the UK both ‘open’ and ‘closed’ intended to compare their effectiveness. Information was collected from inmates and prison staff through a number of exercises designed to assess the social atmosphere of the prison and how they felt about it. The book finishes with a chapter which discusses the policy implications of their findings. Today it can be read in its historical context.

Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic option...

Biosimilars have been in clinical use for more than 10 years, and evidence from more than 700 million patient-days’ exposure shows that approved biosimilars can be used as safely and effectively as their originator biologics. And yet concerns about these drugs persist, particularly in therapy areas where they are recent additions to the formulary. It is vital to address these concerns so that clinicians can prescribe biosimilars with confidence, realizing substantial cost savings and impro...

Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic option...

Biosimilars have been in clinical use for more than 10 years, and evidence from more than 700 million patient-days’ exposure shows that approved biosimilars can be used as safely and effectively as their originator biologics. And yet concerns about these drugs persist, particularly in therapy areas where they are recent additions to the formulary. It is vital to address these concerns so that clinicians can prescribe biosimilars with confidence, realizing substantial cost savings and impro...

'A great and educational read..' Amazon 5 star reader review ⭐⭐⭐⭐⭐**'**Would definitely recommend to anyone thinking .' Amazon 5 star reader review ⭐⭐⭐⭐⭐Criminology is a multi-disciplinary subject - but it doesn't have to be difficult. This book, complete with case studies and key facts, forms a course which will take you from beginner or intermediate level to having a confident grasp of th...

A COMPLETE INTRODUCTORY TEXT TO THE FIELD OF PHARMACOGENOMICSThe only pharmacogenomics resource to feature a global author team comprised of PharmDs, MDs, PhDs and social scientists, Pharmacogenomics offers an essential, highly accessible survey of this dynamic discipline. You will find thorough coverage of all need-to-know topics, from individual molecules to systemic diseases, plus an examination of the latest technologies that are constantly reshaping the field. P...

The criminal justice system is wide ranging; from the crimes themselves and policing to the sentencing of offenders and prisons. In this Very Short Introduction Julian V. Roberts draws upon the latest research and current practices from a number of different countries around the world. Focusing on the adversarial model of justice found in common law countries such as the United States, United Kingdom, Canada, and Australia, he discusses topics such as the uses of imprisonment, the...

The focus of early drug development has been the submission of an Investigational New Drug application to regulatory agencies. Early Drug Development: Strategies and Routes to First-in-Human Trials guides drug development organizations in preparing and submitting an Investigational New Drug (IND) application. By explaining the nuts and bolts of preclinical development activities and their interplay in effectively identifying successful clinical candidates, the book helps pharmaceu...

The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes ...

This practical handbook follows the successful flexicover format of Blackstone's Police Operational Handbook and is designed to complement that publication by offering guidance on good practice in core policing areas. Aimed at junior patrol officers, student officers and trainee detectives, it draws together practical advice across a wide range of police duties, along with extracts and explanations of official policy and guidance from ACPO, the National Policing Improvement Agency and the Nat...

This book provides the most comprehensive and authoritative book yet published on the subject of criminal investigation, a rapidly developing area within the police and other law enforcement agencies, and an important sub discipline within police studies.The subject is rarely out of the headlines, and there is widespread media interest in criminal investigation. Within the police rapid strides are being made in the direction of professionalizing the criminal investigation process, ...